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Background: Trials of interventions for delirium in various patient populations report 
disparate outcomes and measures but little is known about those used in palliative care trials. 
A core outcome set promotes consistency of outcome selection and measurement. 
Aim: To inform core outcome set development by examining outcomes, their definitions, 
measures and time-points in published palliative care studies of delirium prevention or 
treatment delirium interventions. 
Design: Prospectively registered systematic review adhering to Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses. 
Data sources: We searched six electronic databases (1980-November 2020) for original 
studies, three for relevant reviews, and the International Clinical Trials Registry Platform for 
unpublished studies and ongoing trials. We included randomised, quasi-randomised, and non-
randomised intervention studies of pharmacological and non-pharmacological delirium 
prevention and/or treatment interventions. 
Results: From 13/3244 studies (2863 adult participants), we identified nine delirium-specific 
and 13 non-delirium specific and outcome domains within eight Core Outcome Measures in 
Effectiveness Trials (COMET) taxonomy categories. There were multiple and varied outcomes 
and time points in each domain. The commonest delirium specific outcome was delirium 
severity (n=7), commonly using the Memorial Delirium Assessment Scale (6/8 studies, 75%). 
Four studies reported delirium incidence. Non-delirium outcomes included mortality, agitation, 
adverse events, other symptoms, and quality of life. 
Conclusion: The review identified few delirium interventions with heterogeneity in outcomes, 
their definition and measurement, highlighting the need for a uniform approach. Findings will 
inform the next stage to develop consensus for a core outcome set to inform delirium 
interventional palliative care research. 
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The need for interventional research evaluating approaches to prevent and treat delirium has 
been recognized internationally, including in palliative care. Trials of interventions for delirium 
in various patient populations report disparate outcomes and measures but little is known about 
the outcomes used in palliative care trials. 
What this paper adds 
This review demonstrates the limited number of interventions targeting treatment and 
prevention of delirium in palliative care, and the disparate approaches used to evaluate their 
outcomes. 
Implications for practice, theory and policy 
The findings of this review highlight the need for a core outcome set to inform delirium 
interventional palliative care research.  
Utilising common outcomes in clinical trials of delirium prevention and treatment in palliative 
care will enhance capacity to compare and synthesis findings, and their subsequent application 





Delirium is a serious neuropsychiatric disorder in people with progressive life threatening 
illness, with high prevalence that exponentially increases as the person is closer to end of life.1 
Delirium symptoms cause distress for the person themselves, their family, and the health 
professionals who care for them.2 Delirium is associated with significant morbidity, and 
increases risk of functional impairment, cognitive decline and other medical complications. In 
advanced illness, delirium is an independent predictor of mortality and can herald transition 
into the end of life period.3  
The need for interventional research to evaluate approaches to better prevent and treat delirium 
has been recognized internationally, including in palliative care.4 However, no consensus that 
takes patient, family and expert views into account exists to guide researchers to select study 
outcomes and their corresponding measures. This has led to variability in outcome selection 
and measurement, jeopardizing efforts to improve clinical care through comparison, leverage 
and synthesis of existing evidence. There are significant gaps in knowledge to inform optimal 
delirium care for people receiving palliative care, with limited studies of comparative 
effectiveness and harms of interventions to prevent and/or treat delirium. 
The development of a core outcome set is one method of promoting consistency of outcome 
selection and measurement among studies evaluating similar interventions in similar 
populations.5 Core outcome sets are established using rigorous processes: including, firstly, 
identification of outcomes and measures in published and ongoing studies; interviews with 
patient and family members to ascertain outcomes important to them; followed by iterative 
consensus processes involving both those who design and use research, including patients and 
their family.6, 7 The value of a core outcome set has been recognised in other specialties for 
more than two decades,8 but they have only more recently been considered in the field of 
palliative care.9-11 A core outcome set facilitates consistent outcome use following their 
development, as exemplified by the rheumatoid arthritis core outcome set published in 1994,12 
which has been used by over 80% of registered trials since then.13 
Therefore, as the first step towards the development of such a core outcome set for studies of 
interventions designed to prevent and/or treat delirium in palliative care, our aim was to 
evaluate the scope and variability of outcomes, their definitions, measures, and timing of 
measures from published clinical studies of interventions, including quality improvement 




delirium survivors and family members, will subsequently be used to inform development of a 
Delphi questionnaire to identify outcomes considered critically important for inclusion in the 
delirium palliative care core outcome set. 
Methods 
Design 
Systematic review with narrative synthesis of outcomes and measures reported in published 
and ongoing trials of interventions to prevent or treat delirium in palliative care. Data are 
reported according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA)15 and core outcome set methods as recommended by Core Outcome Measures in 
Effectiveness Trials (COMET).14 
Search strategy 
Data sources 
Our systematic review and core outcome set methods are outlined in detail in the published 
Del-COrS study protocol.14Using an iteratively designed search strategy informed by two 
senior information specialists, we searched the following databases from 1980 to 25 November 
2020: Ovid MEDLINE, Ovid MEDLINE In-Process & Other Non-Indexed Citations, 
CINAHL, Embase Classic+Embase, PsycINFO, and Web of Science. We also searched for 
relevant systematic reviews in the Cochrane Library, PROSPERO, and Joanna Briggs and 
unpublished studies and ongoing trials on the International Clinical Trials Registry Platform 
(http://apps.who.int/trialsearch), adjusting vocabulary and syntax as appropriate. We limited 
inclusion to human studies published in English. Reference lists of relevant systematic reviews 
and meta-analyses identified in the search were examined for additional eligible studies. 
Study selection 
Two investigators in pairs (IF, PL, MA, NS, JB, AH, MG, IAD) independently screened for 
studies of pharmacological and non-pharmacological interventions for delirium prevention, 
treatment, or both, in patients in palliative care or palliative care type settings; at both 
title/abstract and full text review stages using CovidenceTM software. Discrepancies were 
resolved through discussion. 
Palliative care patients and settings were defined using the method developed by Lawlor et al 
(2019).16 This includes patients in the following settings: i) admitted to inpatient palliative care 
or hospice unit; ii) received a hospital consult from a palliative care team; or iii) under the care 




palliative care indicator diagnosis; or had cancer or AIDS as a progressive life-threatening 
illness and unequivocally eligible for palliative care referral, but study assessments were 
conducted by an oncology, psychiatry, psycho-oncology or supportive care service.16  We 
included randomised (individual, cluster, and cross over), quasi-randomised, and non-
randomised intervention studies. 
Data extraction 
Two investigators in pairs (IF, MA, JB, PL, AH, ID, MG) independently extracted study 
characteristics, intervention type, verbatim descriptions of primary and secondary outcomes 
and any rationale for their selection, measurement tools, measurement initiation, 
discontinuation, frequency and timing, and who measured outcomes, using a specifically 
designed and piloted extraction form. All data extraction was checked by a third person (IAD, 
MG) and discrepancies were resolved through discussion. 
Quality assessment 
Two investigators in pairs independently assessed: quality of describing and reporting 
outcomes using the six question MOMENT study scoring system (range 0 to 6), with a score 
of ≥4 representing high quality outcome reporting;17 risk of bias for randomised and quasi-
randomised studies using the Cochrane Risk of Bias tool18 and for non-randomised studies 
using the Scottish Intercollegiate Guidelines Network (SIGN) checklist.19 Discrepancies were 
resolved through discussion, and consultation with a third reviewer if necessary. 
Data synthesis 
Two investigators (MA, AH) grouped outcome descriptions into outcome domains considered 
specific to delirium, utilising 10 domains developed from our systematic review of outcomes 
for intensive care unit trials in delirium;20 namely, incidence, prevalence, subtype, severity, 
duration or resolution; time to onset; time delirium free; time delirium and coma free; and/or 
time to resolution. Additional domains were developed when outcomes identified in studies 
did not fit under these 10 domains. Non-delirium specific outcomes were grouped by the 
COMET core domains under the relevant category (n=38) of the COMET taxonomy.21 All 
authors reviewed and agreed upon the final list of outcome domains and assignment to COMET 
taxonomy categories. Discrepancies were discussed to reach agreement. The proportion of 
studies reporting each outcome domain was identified, as well as it was study’s primary 
outcome. The proportion of studies using each measurement tool for delirium-specific outcome 




time-points, measurement frequency, and who measured outcomes. The frequency of use of 
each non-delirium-specific outcome domain across included studies was also calculated. 
Results 
Study characteristics 
We screened 3244 title/abstracts, reviewed 56 full-text articles and identified 13 studies 
meeting our inclusion criteria,22-34 totalling 2863 adult participants (≥18 years) (Figure 1). 
Three of the included studies26-28 had relevant protocol papers35-37 which provided additional 
detail of their reported trial. Eight studies (62%) were completed randomised controlled 
trials.22-29 The five remaining studies included an historical control study,30 a before and after 
study,31 and three non-randomised studies.32-34  
These studies were conducted in palliative care units/inpatient hospices (n=5),25, 28, 30, 31, 36 
admitted patients in both palliative care unit/hospice and hospital settings (n=3),23, 26, 29 hospital 
only (n=4),24, 32-34 and in the community (n=1).22 
Six studies 26-28, 30, 31, 34 explored an intervention to prevent delirium, six studies23-25, 29, 32, 33 
were of a delirium treatment intervention, and one evaluated an intervention to both prevent 
and treat delirium.22  
[Insert Figure 1 here] 
Pharmacological agents were the most common interventions (n=8).23-25, 28, 29, 32-34 One study 
assessed a non-pharmacological intervention,27 and four studies examined standardised 
protocols or bundles of interventions including parenteral hydration protocols22, 26 or protocols 
with both non-pharmacological and pharmacological (e.g. medication changes with opioid 
substitution) components30, 31(Table 1). 
[Insert Table 1 here] 
Delirium-specific outcome domains 
We identified nine delirium-specific outcome domains (Table 2). Delirium severity was the 
most common primary or secondary outcome reported,22-25, 28, 31-33 followed by delirium 
incidence (n=4)27, 28, 31, 34 and delirium symptoms (n=3).22, 23, 25 In studies where delirium 
symptoms were explicitly an outcome of interest this was assessed either using items of the 
Nursing Delirium Screening Scale (n=2) and in one study by outcome assessor recall of the 




with one study using days of delirium with a clear definition of delirium resolution;31 and the 
other, using days with delirium before death which was not clearly defined34 (Table 3). 
[Insert Table 2 here] 
Delirium-specific measures 
Of the eight studies which reported delirium severity,22-25, 28, 31-33 the Memorial Delirium 
Assessment Scale was the most common measure, used in 6/8 (75%) studies (Table 3). 
Delirium incidence was determined using a screening tool (Delirium Observation Screening 
Scale, Confusion Rating Scale, or Nursing Delirium Screening Scale [one study each]) at least 
daily, followed by a diagnostic assessment using DSM-IV (Diagnostic and Statistical Manual 
of Mental Disorders – version IV) criteria or the CAM (Confusion Assessment Method) 
diagnostic algorithm.28, 31, 34, 36 Measurement for delirium-specific outcome domains generally 
commenced on admission or at baseline, with highly variable timing of measurement (first 
measurement timing ranged from 2 hours after intervention to day 4). Two studies did not 
report measurement frequency.30, 34 Delirium outcome assessors included attending 
physicians,28, psychiatrists,32-34 members of the research team,22, 23, 25, 28 psychologists,24 family 
caregivers25 and/or nurses.23-25, 27-31 
Other outcome domains 
Measurement for delirium-specific outcome domains generally commenced on admission or 
at baseline, with highly variable timing of measurement (first measurement timing ranged from 
2 hours after intervention to day 4). Two studies did not report measurement frequency.30, 34 
Delirium outcome assessors included bedside nurses, physicians, psychologists, or members 
of the research team, and one study included input from family caregivers (Table 3). 
[Insert Table 3 here] 
Other outcome domains 
We identified 13 non-delirium specific outcome domains, sitting under the five core areas in 
the COMET taxonomy, and eight COMET taxonomy categories (Table 4). Common outcomes 
(Table 5) included mortality (n=7),22, 23, 25, 26, 28, 29, 31 agitation (n=5)22, 23, 25, 26, 30 (most 
commonly assessed using the Richmond Agitation-Sedation Scale [4/5 studies]), and adverse 
effects of neuroleptics (n=5).23-25, 32, 33 Agitation was classified as non-delirium specific, as in 
people with life-threatening illness and in the end-of-life context, agitation is not necessarily 
delirium-specific and can have multiple contributing factors, such as pain and other symptoms, 




pain and other symptoms (such as breathlessness, nausea, fatigue, depression, anxiety, appetite, 
drowsiness, wellbeing, sleep) and quality of life. Studies ranged from reporting only one to up 
to five outcomes within the non-delirium specific domains. 
[Insert Table 4 here] 
[Insert Table 5 here] 
Risk of bias assessment 
MOMENT criteria and risk of bias 
Of the 13 studies, seven studies22, 23, 25-27, 29, 31 (53%) were considered high quality scoring an 
aggregate of four or higher out of a possible score of six, using the MOMENT criteria (See 
Table 6). Of the eight randomised trials reporting study results,22-29 four were considered low 
risk of bias,22, 23, 25, 28 and four high risk of bias24, 26, 27, 29 (See Supplement 1). Of the remaining 
five non-randomised studies30-34 (See Supplement 2), one was rated as acceptable quality33 and 
four were rated unacceptable quality.30-32, 34 
[Insert Table 6 here] 
Discussion 
This systematic review, conducted to inform development of a core outcome set for clinical 
trials of interventions to prevent and/or treat delirium in palliative care, identified 13 delirium 
intervention studies in palliative care. Our review identified nine delirium-specific and 13 non-
delirium specific outcome domains relating to eight of the 38 COMET taxonomy categories. 
There was heterogeneity in the outcome domains, description of outcomes within domains, 
selected measures, and measurement time-points (both frequency and discontinuation).  
Delirium severity predominated as the delirium specific measure particularly in treatment 
intervention studies, most commonly measured by the Memorial Delirium Assessment Scale . 
The second most frequent was delirium incidence28, 31, 34, 36 with a key issue the variability in 
assessment frequency and measurement approach.34 
The non-delirium outcomes were varied, most commonly mortality, presence and degree of 
agitation (predominantly measured using the Richmond Agitation-Sedation Scale), and 
adverse effects of neuroleptics. Less frequent outcomes were cognitive function, pain and other 




In comparison this review identified a paucity of empirical studies, with fewer non-delirium 
outcomes identified in palliative care studies than a similar review of studies of delirium 
treatment and/or prevention trials and their outcomes in the intensive care unit.20  
Outcomes inclusive of delirium-related symptoms such as disorientation and perceptual 
disturbance, agitation, pain and sleep difficulties were used in most of the included studies, 
which is not surprising given their clinical use in the management of delirium in the palliative 
setting. Only one study took the approach of considering hallucinations as a separate outcome, 
despite this feature being described by palliative medicine specialists as the common clinical 
rationale for pharmacological intervention in palliative care.38 Within their secondary 
outcomes, one study25 reported frequency of visual, tactile and auditory hallucinations 
(alongside assessment of six other delirium symptoms) by daily recall by bedside nurses and 
carers, with other studies including hallucinations within perceptual disturbances 22 23 25 28 32 33 
(which includes studies which utilized the Memorial Delirium Assessment Scale would have 
also collected data on perceptual disturbance (item 7)).  Measurement of delirium-related 
symptoms was mostly proxy-rated (bedside clinician or researcher). The use of items within 
delirium severity instruments to assess symptom profile was not an approach seen. Delirium 
raises specific challenges in capturing patient-reported symptoms and direct understanding of 
the impact of interventions on patient experience, and the circumstances where this may be 
possible should be further explored.  
Frequent screening is essential due to the sudden onset and fluctuating course of delirium, yet 
there was considerable variability in the frequency of delirium screening or delirium severity 
assessment. Few studies considered delirium recurrence or delirium duration. There was also 
limited consideration of endpoints for measurement of delirium duration. This is an important 
factor in palliative care where a common scenario is a delirium episode of short duration due 
to death, which would not signify an improvement in delirium. Studies did not articulate how 
participants who became unconscious were assessed prior to death for all outcomes of interest 
(nor did they report the time period the person was unconscious), which is important to consider 
in palliative care, as in clinical practice delirium symptom management commonly continues 
during this period. Interestingly, though survival was measured, the distinction between death 
as potential adverse event related to the study intervention was less clearly defined. Survival 




There are no international guidelines recommending the optimal measures for delirium 
screening and delirium severity assessment in palliative care. Measurement selection within 
palliative care clinical trials is often guided by limited psychometric evaluation in the cancer 
population (given the relatively high proportion of cancer patients within palliative care 
settings), reflecting the high proportion of included studies using the Memorial Delirium 
Assessment Scale.39 
Outcomes not reported in the included studies included caregiver experience or needs,40 
bereavement outcomes41 and recall of the delirium experience,42, 43 despite these being clearly 
identified in the literature as important in palliative care settings and for which measures exist.2, 
44 Other outcomes not reported include aspects of the delirium experience for which there are 
no existing measures; for example, symptom unpleasantness, symptom intensity, emotional 
distress, or delirium-specific health-related quality of life. Assessment of resource use such as 
healthcare utilization in the reported trials was also limited, which hinders optimal health 
economic analyses in delirium trials in this area. 
Our next steps of the core outcome set development will be to seek consensus on  core outcome 
set domains, and subsequently on the optimal measures, tool, frequency and outcome assessor 
for delirium prevention and/or treatment effectiveness trials in palliative care.14 Consideration 
of whether different outcomes are more relevant in specific situations, for example for delirium 
which occurs in the last hours to days of life, will be critical part of this process. 
Strengths and limitations 
This review used rigorous methods to identify relevant studies, extract data, and categorise 
outcomes using the COMET taxonomy. The search strategy, developed for a series of 
systematic reviews undertaken within the delirium core outcome set,14 used a range of search 
terms to reflect the evolution of terms used to define delirium over the past four decades. We 
used an inclusive method to define palliative care patients and settings, enabling the broadest 
approach to consider outcomes and measurement relevant to this patient population. For 
pragmatic reasons, we excluded studies not reported in English. 
Conclusion 
From 13 published interventional studies, we identified nine delirium-specific and 13 non-
delirium specific outcome domains relating to eight of the 38 COMET taxonomy categories. 
Heterogeneity of outcome domains, description of outcomes within domains, selected 




need for a more uniform approach in this setting. These findings will inform a consensus 
process to agree a core outcome set  for use in future trials of interventions to prevent and/or 
treat delirium in palliative care. 
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Figure 1: PRISMA flowchart
Full text articles excluded, 
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(n = 43) 
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(n =56) 
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(n = 13) 
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Table 1 Study Characteristics 
N = 13 studies n  
Study design  
Double blind RCT22, 23, 25 3 
Open label RCT24, 26 2  
Clustered RCT27 26 2 
Single blind RCT29 1 
Historical control study30 1  
Before and after study31  1 
  Non-randomised study32-34 3 
Country   
USA22, 25, 32, 33 4  
Canada28, 31 2  
Japan30, 34 2 
Australia23, 27 2 
United Kingdom26 1  
Taiwan24 1  
The Netherlands 29 1 
Population  
Adults only 13 
Setting   
Palliative care unit or inpatient hospice25, 27, 28, 30, 31 5  
Hospital palliative care24, 32-34 4 
Palliative care unit/hospice and hospital23, 26, 29 3 
Community palliative care22 1 
Palliative service model   
Direct care22-31, 34 11 
Not reported32, 33  2 
Disciplines involved in service  





Not reported24, 32, 33 3 
Physician type directing patient care  
Palliative care22, 23, 25-27, 31, 35 7 
Psychiatrists24, 32, 33 3 
Not reported29, 30, 34 3 
Delirium study objective  
Primary 8 
Secondary 5  
Study intervention aim  
Prevention26-28, 30, 31, 34 6  
Treatment23-25, 29, 32, 33 6  
Both22 1  
Study intervention  
Pharmacological to prevent and/or treat delirium23-25, 28, 29, 32-34 8  
Bundle to prevent and/or treat delirium#22, 26, 30, 31 4  




RCT: randomised controlled trial; # protocol or bundle included interventions which had both 




Table 2: Number of studies reporting the identified delirium-specific outcome domains (overall, by primary outcome and intervention 
type) 
Domain Overall (all 
included studies) 
(n = 13) 
primary outcome of the study 
in identified delirium-specific 
domain 











and treatment  
(n = 1) 
Delirium severity  8 3 2 5 1 
Delirium incidence 4 2 4 0 0 
Delirium symptoms 3 1 0 2 1 
Duration of first delirium 
episode  
1 0 1 0 0 
Duration of terminal delirium 
from occurrence to death  
1 0 1 0 0 
Delirium resolution  2 0 1 1 0 
Proportion of patient-days with 
delirium symptoms  
1 0 1 0 0 
Delirium free survival  2 1 1 0 0 















Table 3: Measures for delirium specific outcomes by COMET taxonomy domains 
Physiological/clinical (psychiatric outcomes) 
 Severity (n=8) 
Study  Measure Commenced Discontinued Frequency Outcome assessor 
Lawlor 202028 MDAS; CGR Admission Until study 
discontinuation or up 
to 48 h after the trial 
medication has 
stopped 






Hui 201725 MDAS Baseline Discharge 2, 4, and 8 hours 
and then daily 
until discharge 
Research team 
Agar 201723 MDAS Baseline Until study 
discontinuation  
Daily Research team 
Bruera, 201222 MDAS Baseline  When the patient 
discontinued the 
study 
At baseline and day 
4 +/- 2 days for 
week 1, then every 
3 to 5 days 
Research team 
Boettger, 201132 MDAS* Baseline  Day 7 Baseline (T1), 2-3 
days (T2) and 4-7 
days (T3) 
Psychiatrist  
Boettger, 2011b33 MDAS* Baseline Day 7 Baseline (T1), 2-3 
days (T2) and 4-7 
days (T3) 
Psychiatrist 
Gagnon, 201031 CRS From commencement 
of incident delirium 
Resolution of the 
delirium episode or 
death 
Every 8 hours  Nurse 
Lin, 200824 DRS-c* Baseline  One week after 
giving the first dose 
of antipsychotic 
At baseline (T0), at 
24 hours (T1) at 48 
hours (T2) and at 1 






the first dose of 
antipsychotic (T3) 
Incidence (n=4) 




Not reported Not reported Three times daily  Psychiatrist  
Gagnon, 201031 CRS, followed by 
CAM diagnostic 
algorithm* 
Admission  Death Every 8 hours   Nurse 
Hosie, 202027 Nu-DESC, followed 
by delirium diagnosis 
using DSM-IV criteria 
& DRS-R-98  
Admission  Day 7 after 
admission  
Daily, at end of 
shift  
Nurse  
Lawlor 202028 Nu-DESC, followed 
by CAM rating within 
24h 
Admission Until study 
discontinuation or up 
to 48 h after the trial 
medication has 
stopped 




Delirium symptoms (n=3) 
Hui 201725 Recalled frequency of 
6 delirium 
symptoms: 
- disorientation to time 
- disorientation to 
place 
- visual hallucinations 
- tactile hallucinations 
- auditory 
hallucinations 













Baseline Study discontinuation Every 8 hours Bedside nurse, 
research team 
Bruera, 201222 Nu-DESC Baseline  When the patient 
discontinued the 
study 
At baseline and day 
4 +/- 2 days in week 




Duration of first delirium episode (n =1) 
Gagnon 201031 Mean CRS score 
<0.33 for six 
consecutive 8 hour 
shifts 
First episode of 
delirium 
Resolution of 
delirium episode or 
death 
Not reported  Nurse  
Duration of terminal delirium from occurrence to death (n =1) 
Arai, 201334 DOS followed by 
psychiatric diagnosis 
using DSM-IV criteria 
Not reported Not reported Not reported  Psychiatrist  
Resolution (n=2) 
van der Vorst 202029 Time from 
randomisation to 
resolution of delirium 
(number of days); 
Delirium resolution 
defined as DRS-R-98 
severity score of < 
15.75 with decline of 
At DOS score ≥3 Maximum daily dose 








total score of at least 
4.5 points. 
Gagnon, 201031 CRS. A delirium 
episode was 
considered resolved if 
the mean CRS score 
during six consecutive 
8 hour work shifts 
was 0.33 or less 
following an episode 
of incident delirium. 
Admission Death Every 8 hours  Nurse  
Proportion of patient-days with delirium symptoms (n=1) 
Gagnon, 201031 CRS Admission Death Every 8 hours   Nurse  
Delirium free survival (n=2) 
Gagnon, 201031 Not reported  Admission  Death Every 8 hours   Nurse 
Lawlor, 202028 Nu-DESC, followed 
by CAM rating within 
24h 
Admission Until study 
discontinuation or up 
to 48 h after the trial 
medication has 
stopped 




Hyperactive delirium (n=1)  
Morita, 200330 Psychomotor activity 
item (9) of MDAS* 
Not reported  Not reported Not reported Nurse 
*Indicates was primary outcome 
DOS: Delirium Observation Screening Scale; CAM: Confusion Assessment Method; CGR: Clinician Global Rating; CRS: Confusion Rating Scale; DRS-R-
98: Delirium rating RScale – revised 98, DRS-c: Delirium Rating Scale – Chinese; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders – version 





Table 4: Other outcomes grouped according to COMET taxonomy 




Death Mortality/survival (1) Hui, 201725 - 
  Agar, 201723 
Bruera, 201322 
Gagnon, 201031 
Davies, 201826  
Lawlor, 202028 














Other symptoms (9) Hui, 201725 









Dehydration symptoms (9) Bruera, 201322 Yes 
Hydration status (9) 
 
  
Life Impact Physical Functioning (25) Boettger, 201132 - 
  Boettger, 2011b33 - 
  
Emotional Functioning/wellbeing (28) 
 





Cognitive function (29)  





















    













































Table 5: Measurement of other reported outcomes reported by COMET taxonomy domains 
COMET outcome domain and specific outcomes   
Death  
Study  Measure Commenced Discontinued Frequency Outcome assessor 
Hui, 201725 NA Baseline Last day of follow-up 
or death  
Alive at discharge, 
overall survival 
Research team 
Agar, 201723 NA Baseline Last day of follow-up 




Bruera, 201222 NA Study enrolment Last date of follow-up 
or death  
Baseline and day 
4±2 days for the 
first week then 




Gagnon, 201031 NA NR  NR NR Research team 
Davies, 201826 NA NR NR NR Research team 
Lawlor, 202028 NA NR Last date of follow up 
or death 
NR Research team 
Van de Vorst, 
202029 
NA NR Last date of follow up 
or death 
NR Research team 
Physiological/clinical  
Pain 
Arai, 201334  NRS ranging from 0 to 10 




2 days before death  Days 1, 3 and 10 
after the first 
intervention of the 
palliative care team 
and 2 days before 
death 
Clinical team 
Davies, 201826 NR On intervention 
commencement 





Lawlor, 202028  ISI D1 (Study Day 1), 
D14 ± 2 days and 
D28 ± 2 days 
D28 ± 2 days D1 (Study Day 1), 
D14 ± 2 days and 
D28 ± 2 days 
Nurse  
Hui, 201725 ESAS 
 
Baseline Until discharge Daily Participant, 
caregiver proxy 
rater if required 
Davies, 201826 NR After intervention Unclear Four hourly Research team 
Bruera, 201322 ESAS (dehydration 
symptoms of fatigue, 
myoclonus, sedation and 
hallucinations items) 
+UMRS  
Baseline  Until the patient was 
off the study (patient 
was unresponsive, 
developed progressive 
coma or died)  
 
Baseline and day 
4±2 days for the 
first week and then 
every 3 to 5 days 
until study 
discontinuation 
Research team  








Bruera, 201322 Dehydration assessment 
scale  
Baseline  Until the patient was 
off the study (patient 
was unresponsive, 
developed progressive 
coma or died)  
 
Baseline and day 
4+/-2 days for week 
1 then every 3 to 5 
days until patient 
discontinued the 
study    
Research team  
Life impact  
Physical functioning 
Boettger, 201132 KPS Baseline  Day 7 
 
Baseline (T1), 2-3 
days (T2) and 4-7 
days (T3) 
Clinical team 




Initial diagnosis of 
delirium (T1) and 
repeated at 2 – 3 






Hosie, 201927 AKPS Baseline Day 7 Baseline and day 7 Clinical team 
Agar, 201723 AKPS Baseline  Baseline Research team 
Emotional functioning 




At DOS score ≥3 Maximum daily dose 






i) Degree of agitation (n=5)   
Hui, 201725 RASS Baseline Death or discharge 0.5, 1, 1.5, 2, 3, 4, 
5, 6, 7, and 8 hours, 
then daily 
Bedside nurse  
Agar, 201723 RASS Baseline Until study 
discontinuation 
Daily Nurse 
Davis, 201826 mRASS+ administration of 
antipsychotic or other 
sedative 
Within 4 hours of 
commencement of 
intervention 
Until death, survival ≥ 
14 days or withdrawal 
from the study  
Every 4 hours Not reported 
Bruera, 201322 RASS Baseline Until the patient 




coma or died)  
 
baseline and day 
4+/-2 days for first 
week and then 




Morita, 200330 ADS and MDAS items* Not reported Not reported  Not reported  Nurse 
ii) Communication capacity (n=2)  
Hui, 201725 Communication capacity 
(patient ability to hear, 
speak and understand) 
baseline Not reported daily Bedside nurse, 
caregiver 








Global Quality of life   
Agar, 201723 EORTC QLQ C30 
FACIT – Pal  
Delirium resolution Not applicable Once at delirium 
resolution 
Research team 
Bruera, 201322  FACIT-F Baseline  Until the patient left the 
study  
Baseline and day 7  Research team  
 
Delivery of care 
i) Level of adherence to study  
Hosie, 201927  completed delivery of 
intervention domains  
Admission  Day 7 after admission Daily for the first 





Gagnon, 201031  CRS completion rates per 
group  
Beginning of study  End of study   NA  Nurse  
Davies, 201826 Continuation of parenteral 
hydration 
Beginning of study End of study NA Research team 
Resource use 
Need for further intervention 
Agar, 201723 Midazolam use (dose/ 
frequency) 
Baseline End of study Daily Research team 
Lin, 200824 Midazolam use 
(dose/frequency) 
Baseline End of study ? ? 
Hui, 201725 Additional neuroleptic use After intervention 
commencement 
8 hours NA Bedside 
nurse/research 
team 
Adverse events (adverse events/effects) 
Side effects of neuroleptics  
Boettger, 201132 Abbreviated UKU  Baseline  Day 7 Baseline, day 2-3 
and day 4-7 
Clinical team 
Boettger, 2011b33 Abbreviated UKU Initial diagnosis of 
delirium 
Day 7  Initial diagnosis of 
delirium, day 2-3 





Van de Vorst, 
202029 
TRAE according to the 
CTCAE version 4.03 
At DOS score ≥3 Maximum daily dose 





Agar, 201723 Extrapyramidal Symptom 
Rating Scale 
Baseline Day 3 Daily Research team 
Lin, 200824 Side effects of neuroleptics 
– clinician assessment  
Beginning of study End of study Daily Clinical team 
Hui, 201725 Abbreviated UKU Baseline Death or discharge Daily Bedside nurse 
Other adverse events 
Hosie, 201927 
 
Falls, complaints and other 
adverse events deemed 
related to study intervention 
Admission Day 7 after admission daily Research team 
Key: ADS: Agitation Distress Scale; AKPS: Australia-modified Karnofsky Performance Status Scale; KPS: Karnofsky Performance Status 
Scale; CCS: Communication Capacity Scale; CRS: Confusion Rating Scale; CTCAE: Common Terminology Criteria for Adverse Events; DOS: 
Delirium Observation Scale; ESAS: Edmonton Symptom Assessment System; EORTC QLQ C30: European Organisation for Research and 
Treatment of Cancer Quality of life Cancer Patients – core; FACIT-F: Functional Assessment of Chronic Illness Therapy-Fatigue; FACIT- Pal: 
Functional Assessment of Chronic Illness Therapy – palliative care; FCS: Fainsingers Consciousness Score; ISI: Insomnia Severity Index; 
MDAS: Memorial Delirium Assessment Scale; NR: not reported; NRS: numerical rating score; TRAE: Treatment-related adverse events; 
Memorial Delirium Assessment Scale; NA: not applicable; RASS: Richmond Agitation-Sedation Scale; mRASS: modified Richmond Agitation-
Sedation Scale; UKU: Udvalg for Kliniske Undersogelser Side Effect Rating Scale; UMRS: Unified Myoclonus Rating Scale. 
* Only certain items from each tool were used: The psychomotor activity item (item 9) from MDAS, and the extent of motor anxiety and the 




Table 6: Assessment of MOMENT criteria for included studies 
 Criteria (n = 13) Yes No Unclear 
1 Is the primary outcome clearly stated? 11 2 - 
2 Is the primary outcome clearly defined so that 
another researcher would be able to reproduce its 
measurement? 
9 4 - 
3 Are the secondary outcomes clearly stated? 8 5 - 
4 Are the secondary outcomes clearly defined? 4 7 - 
5 Do the authors explain the use of the outcomes they 
have selected? 
5 7 1 
6 Are methods used to enhance the quality of outcome 
measurement (for example, repeated measurement, 
training) if appropriate? 





Supplement 1: Cochrane risk of bias for included RCTs (n = 8)  

















Supplement 2: SIGN checklist for cohort studies 







1.1 The study addresses 
an appropriate and 
clearly focused 
question. 
Yes Yes Yes Yes Unclear 
1.2 The two groups 
being studied are 
selected from source 
populations that are 
comparable in all 
respects other than the 
factor under 
investigation. 
Yes Yes Yes No Yes* 
1.3 The study indicates 
how many of the 
people asked to take 
part did so, in each of 
the groups being 
studied. 
Unclear No Yes NA NA 
1.4 The likelihood that 
some eligible subjects 
might have the 
outcome at the time of 
enrolment is assessed 
and taken into account 
in the analysis. 
No Yes Yes Unclear No 
1.5 What percentage of 
individuals or clusters 
recruited into each arm 
of the study dropped 
out before the study 
was completed? 
Unclear Unclear Unclear Unclear NA 
1.6 Comparison is 
made between full 
participants and those 
lost to follow up, by 
exposure status. 
No Unclear Yes NA NA 
1.7 The outcomes are 
clearly defined. Yes Yes Yes No Yes 
1.8 The assessment of 
outcome is made blind 
to exposure status. If 
the study is 
retrospective this may 
not be applicable. 
Unclear No Unclear No NA 
1.9 Where blinding was 
not possible, there is 
some recognition that 
knowledge of exposure 
status could have 
influenced the 
assessment of outcome. 
Unclear Yes Unclear No NA 
1.10 The method of 
assessment of exposure 
is reliable. 
Unclear Yes Yes Unclear Yes 
1.11 Evidence from 




demonstrate that the 
method of outcome 
assessment is valid and 
reliable. 
1.12 Exposure level or 
prognostic factor is 
assessed more than 
once. 
Yes Yes Yes Yes 
No 
1.13 The main potential 
confounders are 
identified and taken 
into account in the 
design and analysis. 
Yes Yes Yes Yes 
No 
1.14 Have confidence 
intervals been 
provided? 
No No No No No 
2.1 How well did the 
study minimize the risk 
of bias or confounding? 
Unacceptable Unacceptable Acceptable Unacceptable Unacceptable 
2.2 Taking into account 
clinical considerations, 
your evaluation of the 
methodology used, and 
the statistical power of 
the study, do you think 
there is clear evidence 
of an association 
between exposure and 
outcome? 
Unclear Unclear Unclear Unclear No 
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